<?xml version="1.0" encoding="UTF-8"?>
<gtr:projectOverview xmlns:gtr="http://gtr.rcuk.ac.uk/api"><gtr:projectComposition><gtr:collaborations><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/FE9BECCD-7234-4C3C-8A38-65F10B72AB99"><gtr:id>FE9BECCD-7234-4C3C-8A38-65F10B72AB99</gtr:id><gtr:name>Galecto Biotech</gtr:name></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/8A0FC07A-04CD-4F7A-9095-1D2E6C1D918F"><gtr:id>8A0FC07A-04CD-4F7A-9095-1D2E6C1D918F</gtr:id><gtr:name>University of Hull</gtr:name><gtr:address><gtr:line1>Cottingham Road</gtr:line1><gtr:line4>Hull</gtr:line4><gtr:line5>North Humberside</gtr:line5><gtr:postCode>HU6 7RX</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator><gtr:collaborator url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address></gtr:collaborator></gtr:collaborations><gtr:leadResearchOrganisation url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:department>School of Life Sciences</gtr:department><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:typeInd>RO</gtr:typeInd></gtr:leadResearchOrganisation><gtr:organisationRoles><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/936D002F-A8D1-4A93-AE5D-825ED0903D8D"><gtr:id>936D002F-A8D1-4A93-AE5D-825ED0903D8D</gtr:id><gtr:name>University of Nottingham</gtr:name><gtr:address><gtr:line1>University Park</gtr:line1><gtr:line4>Nottingham</gtr:line4><gtr:line5>Nottinghamshire</gtr:line5><gtr:postCode>NG7 2RD</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>LEAD_RO</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/3A5E126D-C175-4730-9B7B-E6D8CF447F83"><gtr:id>3A5E126D-C175-4730-9B7B-E6D8CF447F83</gtr:id><gtr:name>University College London</gtr:name><gtr:address><gtr:line1>Gower Street</gtr:line1><gtr:line4>London</gtr:line4><gtr:postCode>WC1E 6BT</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/2DB7ED73-8E89-457A-A395-FAC12F929C1A"><gtr:id>2DB7ED73-8E89-457A-A395-FAC12F929C1A</gtr:id><gtr:name>University of Edinburgh</gtr:name><gtr:address><gtr:line1>Old College</gtr:line1><gtr:line2>South Bridge</gtr:line2><gtr:line3>Mayfield Road</gtr:line3><gtr:line4>Edinburgh</gtr:line4><gtr:postCode>EH8 9YL</gtr:postCode><gtr:region>Scotland</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/A1382653-9660-42B5-8658-B7FBD06F5D06"><gtr:id>A1382653-9660-42B5-8658-B7FBD06F5D06</gtr:id><gtr:name>AstraZeneca plc</gtr:name><gtr:address><gtr:line1>2 Kingdom Street</gtr:line1><gtr:postCode>W2 6BD</gtr:postCode><gtr:region>Unknown</gtr:region></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/4A348A76-B2D0-4DDD-804A-CE735A6D3798"><gtr:id>4A348A76-B2D0-4DDD-804A-CE735A6D3798</gtr:id><gtr:name>University of Bristol</gtr:name><gtr:address><gtr:line1>Senate House</gtr:line1><gtr:line4>Bristol</gtr:line4><gtr:line5>Avon</gtr:line5><gtr:postCode>BS8 1TH</gtr:postCode><gtr:region>South West</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/46387D84-F71E-4B7D-8C7D-9C288F113510"><gtr:id>46387D84-F71E-4B7D-8C7D-9C288F113510</gtr:id><gtr:name>Imperial College London</gtr:name><gtr:address><gtr:line1>South Kensington Campus</gtr:line1><gtr:line2>Exhibition Road</gtr:line2><gtr:line4>London</gtr:line4><gtr:postCode>SW7 2AZ</gtr:postCode><gtr:region>London</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/FE9BECCD-7234-4C3C-8A38-65F10B72AB99"><gtr:id>FE9BECCD-7234-4C3C-8A38-65F10B72AB99</gtr:id><gtr:name>Galecto Biotech</gtr:name><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/03D8AFBB-3EA5-4885-B036-BD4F9F4F9849"><gtr:id>03D8AFBB-3EA5-4885-B036-BD4F9F4F9849</gtr:id><gtr:name>University of Sheffield</gtr:name><gtr:address><gtr:line1>Firth Court</gtr:line1><gtr:line2>Western Bank</gtr:line2><gtr:line4>Sheffield</gtr:line4><gtr:line5>South Yorkshire</gtr:line5><gtr:postCode>S10 2TN</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/D1774113-D5D2-4B7C-A412-66A90FE4B96F"><gtr:id>D1774113-D5D2-4B7C-A412-66A90FE4B96F</gtr:id><gtr:name>University of Cambridge</gtr:name><gtr:address><gtr:line1>Lensfield Road</gtr:line1><gtr:line4>Cambridge</gtr:line4><gtr:postCode>CB2 1EW</gtr:postCode><gtr:region>East of England</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/8A0FC07A-04CD-4F7A-9095-1D2E6C1D918F"><gtr:id>8A0FC07A-04CD-4F7A-9095-1D2E6C1D918F</gtr:id><gtr:name>University of Hull</gtr:name><gtr:address><gtr:line1>Cottingham Road</gtr:line1><gtr:line4>Hull</gtr:line4><gtr:line5>North Humberside</gtr:line5><gtr:postCode>HU6 7RX</gtr:postCode><gtr:region>Yorkshire and The Humber</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole><gtr:organisationRole url="http://gtr.rcuk.ac.uk:80/organisation/C842A34F-18F7-454D-A259-FED802368496"><gtr:id>C842A34F-18F7-454D-A259-FED802368496</gtr:id><gtr:name>University of Leicester</gtr:name><gtr:address><gtr:line1>University Road</gtr:line1><gtr:line4>Leicester</gtr:line4><gtr:line5>Leicestershire</gtr:line5><gtr:postCode>LE1 7RH</gtr:postCode><gtr:region>East Midlands</gtr:region><gtr:country>United Kingdom</gtr:country></gtr:address><gtr:roles><gtr:role><gtr:name>COLLABORATOR</gtr:name></gtr:role></gtr:roles></gtr:organisationRole></gtr:organisationRoles><gtr:personRoles><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/7B141CC2-09C5-4864-86B5-A9CAEBCF2531"><gtr:id>7B141CC2-09C5-4864-86B5-A9CAEBCF2531</gtr:id><gtr:firstName>John</gtr:firstName><gtr:otherNames>FRANCIS</gtr:otherNames><gtr:surname>Marshall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/FC303F59-8842-4BCB-A5A3-0C057B836730"><gtr:id>FC303F59-8842-4BCB-A5A3-0C057B836730</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:otherNames>Brian</gtr:otherNames><gtr:surname>Hubbard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/BC278767-476C-4BE4-B737-F11474D9D947"><gtr:id>BC278767-476C-4BE4-B737-F11474D9D947</gtr:id><gtr:firstName>Tricia</gtr:firstName><gtr:surname>McKeever</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/6D9DFF51-8103-42B7-B910-9735C323F164"><gtr:id>6D9DFF51-8103-42B7-B910-9735C323F164</gtr:id><gtr:firstName>Simon</gtr:firstName><gtr:otherNames>Richard</gtr:otherNames><gtr:surname>Johnson</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/C0B64D34-11DD-403C-A2D0-D6161CFD5983"><gtr:id>C0B64D34-11DD-403C-A2D0-D6161CFD5983</gtr:id><gtr:firstName>Alan</gtr:firstName><gtr:otherNames>Christopher</gtr:otherNames><gtr:surname>Perkins</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3B9DED04-55AB-470F-BDC2-E706CE2A12EA"><gtr:id>3B9DED04-55AB-470F-BDC2-E706CE2A12EA</gtr:id><gtr:firstName>Richard</gtr:firstName><gtr:surname>Marshall</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/3B4DAFEF-CDF4-498B-B9DC-5914D96301F4"><gtr:id>3B4DAFEF-CDF4-498B-B9DC-5914D96301F4</gtr:id><gtr:firstName>Gisli</gtr:firstName><gtr:surname>Jenkins</gtr:surname><gtr:roles><gtr:role><gtr:name>PRINCIPAL_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole><gtr:personRole url="http://gtr.rcuk.ac.uk:80/person/9F9446FA-0D69-44BE-AB8E-1148A16C671C"><gtr:id>9F9446FA-0D69-44BE-AB8E-1148A16C671C</gtr:id><gtr:firstName>Andy</gtr:firstName><gtr:surname>Blanchard</gtr:surname><gtr:roles><gtr:role><gtr:name>CO_INVESTIGATOR</gtr:name></gtr:role></gtr:roles></gtr:personRole></gtr:personRoles><gtr:project url="http://gtr.rcuk.ac.uk:80/projects?ref=G0901226"><gtr:id>47CA515C-1321-4F3D-B1AB-6918DDE8E1D5</gtr:id><gtr:title>The evaluation of the avb6 integrin as a biomarkers and therapeutic target for idiopathic pulmonary fibrosis</gtr:title><gtr:status>Closed</gtr:status><gtr:grantCategory>Research Grant</gtr:grantCategory><gtr:grantReference>G0901226</gtr:grantReference><gtr:abstractText>Idiopathic pulmonary fibrosis (IPF) is a disease where the fine, delicate structure of the lungs is replace by a hard, concrete-like substance called fibrous matrix. This prevents the normal functions of the lung, such as the transfer of oxygen from the air to the body, it also leads to irritation and persistent cough. The speed at which this concrete-like matrix is deposited in the lung varies between different people, but ultimately leads to death. Unfortunately it is difficult to predict who will get worse quickly, and who will get worse slowly. Furthermore, there are no treatments that can improve the outlook for people with IPF at the current time. The aim of this study is to develop a biological test that can predict which people with IPF are going to have slowly progressive disease compared with rapidly progressive disease. More importantly these biological tests will hopefully be able to be used to show whether a current, or new treatment, is working in an individual patient. This information will help patients plan their future when the receive a diagnosis of IPF and will help in the development of new treatments for this condition, which are so urgently sought.</gtr:abstractText><gtr:technicalSummary>Idiopathic pulmonary fibrosis (IPF) is a progressive fibrotic lung disease of unknown aetiology. The pathogenesis of IPF is thought to be due to abnormal repair following alveolar epithelial injury within the lung. Current estimates suggest 4500 new cases of IPF each year in the UK, with median survival around 3 years. Furthermore, there has been a progressive increase in the incidence of IPF since the early 1980s. Considerable disease heterogeneity exists both in terms of clinical presentation and survival. However, there are no treatments that reduce the mortality or morbidity, although candidate treatments are emerging. 
The aim of this proposal is to evaluate the alphavbeta6 integrin, which has an established role in the pathogenesis of fibrogenesis, as a potential biomarker in IPF. We will use immunohistochemistry from historical and prospective data sets as well as serum and lavage studies to evaluate alphavbeta6 integrin expression and downstream TGFbeta activation. We will develop a radiolabelled imaging strategy to permit real-time assessement of alphavbeta6 integrin expression which can then be followed longitudinally to assesss disease progression or response to therapy. 
Specifically we aim to: 1) immunotype (alphavbeta6; alphaSMA, PAI-1, HGF) histological samples from patients undergoing surgical biopsies, to accurately determine patients with a poor prognosis compared with other fibrotic lung diseases; 2) develop non-invasive radioimaging (PET/CT and SPECT/CT) of pulmonary alphavbeta6 integrin levels to monitor the presence and progression of pulmonary fibrosis; 3) evaluate bronchoalveolar lavage and serum makers of alphavbeta6 integrin mediated TGFbeta activation in patients with IPF. 
Initial studies will be performed in historical samples from patients with a diagnosis of lung fibrosis to determine whether . The cohort will be recruited within the established clinical network of centres in the whole Trent region, and will aim to recruit up to 225participants. At the time of diagnosis participants will be phenotyped in detail and the cohort will be followed for an average of 2.5 years (range 1 to 4 years). During this time we expect nearly 50% of our cohort to die. We will then determine which factors most accurately predict survival.
The results of this study will provide information regarding prognosis and disease progression in IPF. This information will be used to help plan the timing of therapeutic interventions such as lung transplantation as well as design of efficient clinical trials to alleviate the suffering of patients who suffer from this devastating disease.</gtr:technicalSummary><gtr:fund><gtr:end>2012-12-31</gtr:end><gtr:funder url="http://gtr.rcuk.ac.uk:80/organisation/C008C651-F5B0-4859-A334-5F574AB6B57C"><gtr:id>C008C651-F5B0-4859-A334-5F574AB6B57C</gtr:id><gtr:name>MRC</gtr:name></gtr:funder><gtr:start>2010-01-01</gtr:start><gtr:type>INCOME_ACTUAL</gtr:type><gtr:valuePounds>419472</gtr:valuePounds></gtr:fund><gtr:output><gtr:artisticAndCreativeProductOutputs/><gtr:collaborationOutputs><gtr:collaborationOutput><gtr:collaboratingOrganisation>Galecto Biotech</gtr:collaboratingOrganisation><gtr:country>Sweden, Kingdom of</gtr:country><gtr:description>Nottingham Molecular Pathology Node</gtr:description><gtr:id>08F0E5C1-EAA4-4E2F-8C3A-FC47377A5065</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>Galecto part funding the PhD</gtr:partnerContribution><gtr:piContribution>I am supervising a PhD jointly funded by the MRC and Galecto Biotec</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Hull</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Interstitial Lung Disease Consortium</gtr:description><gtr:id>54E4E429-55A4-4E90-B5E1-9BE7187B52FA</gtr:id><gtr:impact>Data analysis still ongoing</gtr:impact><gtr:partnerContribution>Provided patient samples and data
Provided data analysis
Undertook genotyping</gtr:partnerContribution><gtr:piContribution>Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>AstraZeneca</gtr:collaboratingOrganisation><gtr:country>United States of America</gtr:country><gtr:department>MedImmune</gtr:department><gtr:description>MedImmune MRC-CASE awards</gtr:description><gtr:id>0BFD3E7F-8CCE-4BBB-A27A-EC595F69890B</gtr:id><gtr:impact>None yet</gtr:impact><gtr:partnerContribution>MedImmune will be co-supervising the award.</gtr:partnerContribution><gtr:piContribution>I am supervising a PhD with input from MedImmune having successfully submitted an MRC CASE award.</gtr:piContribution><gtr:sector>Private</gtr:sector><gtr:start>2015-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Leicester</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Genetic Epidemiology</gtr:department><gtr:description>UK Interstitial Lung Disease Consortium</gtr:description><gtr:id>4932D44A-A2AD-46ED-9A7D-D6553B7A719A</gtr:id><gtr:impact>Data analysis still ongoing</gtr:impact><gtr:partnerContribution>Provided patient samples and data
Provided data analysis
Undertook genotyping</gtr:partnerContribution><gtr:piContribution>Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Sheffield</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Interstitial Lung Disease Consortium</gtr:description><gtr:id>2762D3B4-F0E4-410D-8984-54CE4F8985CF</gtr:id><gtr:impact>Data analysis still ongoing</gtr:impact><gtr:partnerContribution>Provided patient samples and data
Provided data analysis
Undertook genotyping</gtr:partnerContribution><gtr:piContribution>Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Cambridge</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:department>Department of Medicine</gtr:department><gtr:description>UK Interstitial Lung Disease Consortium</gtr:description><gtr:id>79CE11B3-8C83-4670-B2BF-6D71453AE845</gtr:id><gtr:impact>Data analysis still ongoing</gtr:impact><gtr:partnerContribution>Provided patient samples and data
Provided data analysis
Undertook genotyping</gtr:partnerContribution><gtr:piContribution>Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University College London (UCL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Interstitial Lung Disease Consortium</gtr:description><gtr:id>8BA8E978-8118-4CE6-A554-93353FC5A18F</gtr:id><gtr:impact>Data analysis still ongoing</gtr:impact><gtr:partnerContribution>Provided patient samples and data
Provided data analysis
Undertook genotyping</gtr:partnerContribution><gtr:piContribution>Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Edinburgh</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Interstitial Lung Disease Consortium</gtr:description><gtr:id>1C56E702-1E29-4C41-BF37-2BD82A8DA510</gtr:id><gtr:impact>Data analysis still ongoing</gtr:impact><gtr:partnerContribution>Provided patient samples and data
Provided data analysis
Undertook genotyping</gtr:partnerContribution><gtr:piContribution>Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>Imperial College London (ICL)</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Interstitial Lung Disease Consortium</gtr:description><gtr:id>B07495E2-AAEB-4D8F-A0DC-9D9C5279037B</gtr:id><gtr:impact>Data analysis still ongoing</gtr:impact><gtr:partnerContribution>Provided patient samples and data
Provided data analysis
Undertook genotyping</gtr:partnerContribution><gtr:piContribution>Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput><gtr:collaborationOutput><gtr:collaboratingOrganisation>University of Bristol</gtr:collaboratingOrganisation><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:description>UK Interstitial Lung Disease Consortium</gtr:description><gtr:id>16B7F4BB-3597-4E36-B7E1-DA718E785BFD</gtr:id><gtr:impact>Data analysis still ongoing</gtr:impact><gtr:partnerContribution>Provided patient samples and data
Provided data analysis
Undertook genotyping</gtr:partnerContribution><gtr:piContribution>Coordinated the genotyping and data analysis of genotype with outcome of patients with Idiopathic Pulmonary Fibrosis</gtr:piContribution><gtr:sector>Academic/University</gtr:sector><gtr:start>2012-01-01</gtr:start></gtr:collaborationOutput></gtr:collaborationOutputs><gtr:disseminationOutputs><gtr:disseminationOutput><gtr:description>Cambridge respiratory Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>177AD5F1-0933-4EAF-8D7E-4437B559040E</gtr:id><gtr:impact>Talk sparked discussion

Collaborative opportunnities</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal College of Physicians and Surgeons Glasgow</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>FA68B5FB-B637-480F-BB3F-34062DD630C8</gtr:id><gtr:impact>Talk sparked discussions afterwards

After my talk slides were requested</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal College of Physicians Advanced Medicine Conference</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CEBC470E-166E-4826-B718-980B9122E385</gtr:id><gtr:impact>talk sparked discussion afterwards

Talk lead to an invited review</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Royal College of Physicians Update</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>510B9B41-98E7-4D2A-9F40-B6AECFF871C3</gtr:id><gtr:impact>Approximately 200 physicians around the west midlands attended and I had discussions about the diagnosis and management of pulmonary fibrosis subsequently</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>https://www.rcplondon.ac.uk/events/regional-update-medicine-west-midlands</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Fibrosis Conference (Rhodes)</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>5BE366ED-E944-486E-9872-EF3D7B6A0D0F</gtr:id><gtr:impact>90 researchers from across organ systems and across the world attended the conference and my talk sparked discussion and debate afterwards.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Professional Practitioners</gtr:primaryAudience><gtr:url>http://www.aegeanconferences.org/src/App/conferences/view/112</gtr:url><gtr:year>2016</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient Day 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>C631129D-925B-4CCE-9E63-B13879E6E097</gtr:id><gtr:impact>100 patients and carers attended, sparking discussion.

Formation of the national IPF Charity Action of Pulmonary Fibrosis</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Keynote/Invited Speaker</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.actionpulmonaryfibrosis.org/</gtr:url><gtr:year>2012,2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Summer BALR meeting in 2013</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>12ABCBDA-0FFB-45FC-9E8C-DC9E74036BA1</gtr:id><gtr:impact>Me and my team organised a two day scientific meeting and accompanying Patient Support day in July 2013. The feedback from the days was outstanding, there was a huge amount of discussion and the attendance at the conference was a record.

Increased collaborations, videos of patient day posted on the pulmonary fibrosis foundation website.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:url>http://www.pulmonaryfibrosis.org/life-with-pf/pff-educational-resources/webinars</gtr:url><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Munich International Autumn School</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>80B8BA7F-6AD7-4ACF-AE0C-BC53A86F2B86</gtr:id><gtr:impact>Large international meeting to the largest Respiratory Research group in Germany that also attracted an audience from access Europe and the world, I delivered two lectures and participated in group workshops with a number of post docs.</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Postgraduate students</gtr:primaryAudience><gtr:url>https://www.helmholtz-muenchen.de/en/press-media/press-releases/.../index.html</gtr:url><gtr:year>2015</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>American Thoracic Society Talk</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>9BD103FF-8BCC-479E-B420-889C16E6FB6A</gtr:id><gtr:impact>Talk sparked questions and discussions afterwards

International collaborations developed</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Nordic Respiratory Society meeting</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>8BAF8BDE-CCCC-4759-A4C3-C5F816062A36</gtr:id><gtr:impact>Talk sparked questions and discussions afterwards

International contacts developed</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>ICLAF 2014</gtr:description><gtr:form>A magazine, newsletter or online publication</gtr:form><gtr:geographicReach>International</gtr:geographicReach><gtr:id>D16CA92D-156A-4676-B0FF-FFBF134ADF15</gtr:id><gtr:impact>Talk sparked discussion

Numerous collaborative requests and possible review</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Patient Priority Day</gtr:description><gtr:form>Participation in an open day or visit at my research institution</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>E1A107ED-5BF1-4E43-8E7B-7C9512694FF1</gtr:id><gtr:impact>110 patients or patient relatives attended a one day conference informing them about their disease (IPF)

Formation of Pulmonary Fibrosis Association Patient Group</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:presentationType>Workshop Facilitator</gtr:presentationType><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2012</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>Tissue Fibrosis: State-of-the-Art</gtr:description><gtr:form>Participation in an activity, workshop or similar</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>41405647-608A-4B0A-ABF4-9C8863BF9840</gtr:id><gtr:impact>Widespread discussions of future collaboration

Tissue Fibrosis Website to be generated</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>British Inflammation Research Association</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>National</gtr:geographicReach><gtr:id>039230BE-163E-489C-AA0A-6ABB0F59517E</gtr:id><gtr:impact>Talked sparked discussion afterwards

Networking opportunites</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2014</gtr:year></gtr:disseminationOutput><gtr:disseminationOutput><gtr:description>London Matrix Group</gtr:description><gtr:form>A talk or presentation</gtr:form><gtr:geographicReach>Local</gtr:geographicReach><gtr:id>51524D0F-B09A-48A7-B506-96123DD09298</gtr:id><gtr:impact>Talk sparked discussion

Collaborative requests</gtr:impact><gtr:partOfOfficialScheme>false</gtr:partOfOfficialScheme><gtr:primaryAudience>Participants in your research and patient groups</gtr:primaryAudience><gtr:year>2013</gtr:year></gtr:disseminationOutput></gtr:disseminationOutputs><gtr:exploitationOutputs/><gtr:furtherFundingOutputs><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Medical Research Foundation Respiratory Disease Call</gtr:description><gtr:end>2019-09-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>5B36BC04-26F2-49C4-89AC-3290EFDEA6FA</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>553341</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Research Grant G1100564</gtr:description><gtr:end>2015-04-02</gtr:end><gtr:fundingOrg>National Centre for the Replacement, Refinement and Reduction of Animals in Research (NC3Rs)</gtr:fundingOrg><gtr:id>BB3DBAA1-E587-4310-87D7-074BB6CA9D54</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2011-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>48000</gtr:amountPounds><gtr:country>Global</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Refining Radiation Models of Fibrosis</gtr:description><gtr:end>2016-03-02</gtr:end><gtr:fundingOrg>GlaxoSmithKline (GSK)</gtr:fundingOrg><gtr:id>E4AE6FD2-7C12-4EF7-9A47-19621FC19AC7</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2014-04-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>200000</gtr:amountPounds><gtr:country>United States of America</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Biogen Idec contract</gtr:description><gtr:end>2016-01-02</gtr:end><gtr:fundingOrg>Biogen Idec</gtr:fundingOrg><gtr:id>0DBEC394-F222-4CA4-8A1C-1BD3EFFDE88E</gtr:id><gtr:sector>Private</gtr:sector><gtr:start>2014-02-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>2400000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Molecular Pathology Node</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:id>FE33545A-43EE-4F41-A5B3-A602D2CFCE55</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2015-10-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>279483</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>Clinical Fellowship</gtr:description><gtr:end>2019-10-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:fundingRef>MR/P001327/1</gtr:fundingRef><gtr:id>16DFC175-279C-44F9-952A-70A8108214A1</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-11-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>250000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:department>Medical Research Foundation</gtr:department><gtr:description>Medical Research Foundation Respiratory Disease Call</gtr:description><gtr:end>2019-06-02</gtr:end><gtr:fundingOrg>Medical Research Council (MRC)</gtr:fundingOrg><gtr:id>D2943C7C-823B-48DD-9AAA-9AA5F0A2EF17</gtr:id><gtr:sector>Charity/Non Profit</gtr:sector><gtr:start>2016-07-01</gtr:start></gtr:furtherFundingOutput><gtr:furtherFundingOutput><gtr:amountPounds>100000</gtr:amountPounds><gtr:country>United Kingdom of Great Britain &amp; Northern Ireland (UK)</gtr:country><gtr:currCode>GBP</gtr:currCode><gtr:currCountryCode>United Kingdom</gtr:currCountryCode><gtr:currLang>en_GB</gtr:currLang><gtr:description>MRC Case Award</gtr:description><gtr:end>2020-09-02</gtr:end><gtr:fundingOrg>MRC-UK</gtr:fundingOrg><gtr:id>6AFC621E-A93C-406B-B3F9-E30B8AFF819D</gtr:id><gtr:sector>Public</gtr:sector><gtr:start>2016-10-01</gtr:start></gtr:furtherFundingOutput></gtr:furtherFundingOutputs><gtr:impactSummaryOutputs/><gtr:intellectualPropertyOutputs/><gtr:otherResearchOutputs/><gtr:policyInfluenceOutputs><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MILD Fibrosis meeting</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>E0163D0F-5A88-4EA1-8759-65AC71147EEC</gtr:id><gtr:impact>Wide ranging update to a range of health care practitioners regarding the diagnosis and treatment of IPF</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE Nintedanib Scoping Workshop</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>CFAECC41-1A17-46FB-B2E7-207C3F113D26</gtr:id><gtr:type>Implementation circular/rapid advice/letter to e.g. Ministry of Health</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>ERS/ATS Clinical Guideline Committee for the Diagnosis of IPF</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>571D8F0A-7251-4832-BCBD-2D48AA2BDA38</gtr:id><gtr:type>Membership of a guideline committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>NICE PAS</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>A9127B4E-1F10-4AAD-805D-A2574725D07B</gtr:id><gtr:impact>Pirfenidone is currently prescribed with under a patient access scheme for which my evidence formed part of the review.</gtr:impact><gtr:type>Gave evidence to a government review</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Workshop on the Future Directions of Pulmonary Fibrosis Research</gtr:description><gtr:geographicReach>North America</gtr:geographicReach><gtr:id>ACDC150E-9475-49D4-BE74-442F92C1AE67</gtr:id><gtr:type>Participation in a national consultation</gtr:type><gtr:url>http://www.atsjournals.org/doi/abs/10.1164/rccm.201602-0254ST?url_ver=Z39.88-2003&amp;rfr_id=ori:rid:crossref.org&amp;rfr_dat=cr_pub%3dpubmed</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Specialist Respiratory Clinical Reference Group</gtr:description><gtr:geographicReach>National</gtr:geographicReach><gtr:id>AD4C584F-F6CD-418B-96E7-1F3B3D8C74D6</gtr:id><gtr:impact>Advising on reorganisation of Specialised Respiratory Services for NHS England</gtr:impact><gtr:type>Participation in advisory committee</gtr:type></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>Editor in Chief Thorax</gtr:description><gtr:geographicReach>Multiple continents/international</gtr:geographicReach><gtr:id>C30EBDE7-16BE-438D-BB80-E6A28BCF5CC2</gtr:id><gtr:impact>As Editor-in-Chief of Thorax (the official journal of the British Thoracic Society and 4th highest Respiratory Journal) we have completely revised the instructions for authors to emphasise scientific rigour with explicit guidelines for research of many disciplines.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type><gtr:url>http://thorax.bmj.com/pages/authors/</gtr:url></gtr:policyInfluenceOutput><gtr:policyInfluenceOutput><gtr:areas/><gtr:description>MILD Fibrosis Meeting</gtr:description><gtr:geographicReach>Local/Municipal/Regional</gtr:geographicReach><gtr:id>273CCD2D-EEFE-4E0B-BA74-180CD43F7092</gtr:id><gtr:impact>No particular change in practice but dissemination of the information regarding the benefits of participating in Clinical Trials.</gtr:impact><gtr:type>Influenced training of practitioners or researchers</gtr:type></gtr:policyInfluenceOutput></gtr:policyInfluenceOutputs><gtr:productOutputs><gtr:productOutput><gtr:description>The Nordic biomarkers that we identified in our Lancet paper Jenkins et al 2015, are now been assessed as theranostic biomarkers in an interventional clinical trial sponsored by Boehringer Ingelheim.
NCT02788474</gtr:description><gtr:id>261259B2-537B-4DF2-ACF9-194DED998001</gtr:id><gtr:impact>These biomarkers are now being assessed in a large number of interventional clinic trials.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Nordic Biomarkers</gtr:title><gtr:type>Diagnostic Tool - Non-Imaging</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02788474</gtr:url><gtr:yearDevCompleted>2016</gtr:yearDevCompleted></gtr:productOutput><gtr:productOutput><gtr:clinicalTrial>true</gtr:clinicalTrial><gtr:description>This is a methodology study to examine the quantification of GSK2634673F binding in humans, with the aim of characterising a robust, non-invasive method to quantify the specific binding signal for the alpha(V)beta6 protein in human tissues. This will be the first time that this micro-dose ligand is administered to humans. The study will consist of three parts; Part A, Part B and Part C. Healthy subjects will be recruited into Parts A and B of the study in order to gain experience with the GSK2634673F positron emission tomography (PET) ligand and to optimise the scanning procedures prior to administration to IPF patients in Part C.</gtr:description><gtr:id>FEB0BAF8-2B9C-49EA-92C1-F2207B8EDC95</gtr:id><gtr:impact>This study will identify whether the avb6 integrin can be used as a PD biomarker for interventional clinical trials.</gtr:impact><gtr:stage>Early clinical assessment</gtr:stage><gtr:status>Under active development/distribution</gtr:status><gtr:title>Humanised PET Ligand</gtr:title><gtr:type>Diagnostic Tool - Imaging</gtr:type><gtr:url>https://clinicaltrials.gov/ct2/show/NCT02052297</gtr:url><gtr:yearDevCompleted>2017</gtr:yearDevCompleted></gtr:productOutput></gtr:productOutputs><gtr:researchDatabaseAndModelOutputs><gtr:researchDatabaseAndModelOutput><gtr:description>We have a collection of over 330 biological samples with matched clinical data from patients with incident IPF</gtr:description><gtr:id>3583A13A-953E-438F-BD95-28A03D43F0F5</gtr:id><gtr:impact>First paper is under review at Lancet and further papers are planned. A number of lectures describing the PROFILE cohort have been delivered and two articles have cited the development of the PROFILE cohort.</gtr:impact><gtr:providedToOthers>true</gtr:providedToOthers><gtr:title>PROFILE Study database</gtr:title><gtr:type>Database/Collection of data</gtr:type><gtr:yearFirstProvided>2013</gtr:yearFirstProvided></gtr:researchDatabaseAndModelOutput></gtr:researchDatabaseAndModelOutputs><gtr:researchMaterialOutputs><gtr:researchMaterialOutput><gtr:description>We have begun collecting blood and lavage from patients with IPF. Some will be stored for sharing after primary analysis</gtr:description><gtr:id>EC4561BC-F638-46FD-BBB8-982678846651</gtr:id><gtr:impact>These biological samples are at an early stage of collection and therefore no impcts have resulted as yet.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Biological samples from patients with IPF</gtr:title><gtr:type>Biological samples</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>As part of the program to assess integrin mediated TGFbeta activity in mice we have developed a lung epithelial specific Gq/11 double and G12/13 double knockout mouse.</gtr:description><gtr:id>0CDA6139-F202-4E49-8AB1-5CC74885EDF5</gtr:id><gtr:impact>These mice are currently being characterised and no notable impacts have yet been reported.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Lung specific G protein null mouse</gtr:title><gtr:type>Model of mechanisms or symptoms - mammalian in vivo</gtr:type></gtr:researchMaterialOutput><gtr:researchMaterialOutput><gtr:description>We can now perform whole lung imaging of avb6 integrin expression</gtr:description><gtr:id>5ECECE89-776C-4642-A5D0-F0766C5DD112</gtr:id><gtr:impact>This technology is being used by us for commercial groups and would be made available to other groups if requested. Studies are ongoing to translate it into a clinical tool.</gtr:impact><gtr:providedToOthers>false</gtr:providedToOthers><gtr:title>Beta6 integrin imaging</gtr:title><gtr:type>Technology assay or reagent</gtr:type></gtr:researchMaterialOutput></gtr:researchMaterialOutputs><gtr:softwareAndTechnicalProductOutputs/><gtr:spinOutOutputs/></gtr:output><gtr:publications><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/6CD32D1A-B579-4FA4-BF6F-1C03FA432ECA"><gtr:id>6CD32D1A-B579-4FA4-BF6F-1C03FA432ECA</gtr:id><gtr:title>Preclinical SPECT/CT imaging of av?6 integrins for molecular stratification of idiopathic pulmonary fibrosis.</gtr:title><gtr:parentPublicationTitle>Journal of nuclear medicine : official publication, Society of Nuclear Medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2cc10d22d69f590782e2539a923e5cc7"><gtr:id>2cc10d22d69f590782e2539a923e5cc7</gtr:id><gtr:otherNames>John AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2013-01-01</gtr:date><gtr:issn>0161-5505</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/A779DA1F-0C68-440D-A2CF-B8B9B6D26D04"><gtr:id>A779DA1F-0C68-440D-A2CF-B8B9B6D26D04</gtr:id><gtr:title>av?6 integrin may be a potential prognostic biomarker in interstitial lung disease.</gtr:title><gtr:parentPublicationTitle>The European respiratory journal</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/79c2eb542f980d519032ac609c55b93d"><gtr:id>79c2eb542f980d519032ac609c55b93d</gtr:id><gtr:otherNames>Saini G</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>0903-1936</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/C28CF950-D520-45DE-A953-C7DC0F68EC57"><gtr:id>C28CF950-D520-45DE-A953-C7DC0F68EC57</gtr:id><gtr:title>Longitudinal change in collagen degradation biomarkers in idiopathic pulmonary fibrosis: an analysis from the prospective, multicentre PROFILE study.</gtr:title><gtr:parentPublicationTitle>The Lancet. Respiratory medicine</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/0f4736589f4d300b8fcd84212396e994"><gtr:id>0f4736589f4d300b8fcd84212396e994</gtr:id><gtr:otherNames>Jenkins RG</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2015-01-01</gtr:date><gtr:issn>2213-2600</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/74CB3207-A23B-4571-9BAF-61F39A05EAE7"><gtr:id>74CB3207-A23B-4571-9BAF-61F39A05EAE7</gtr:id><gtr:title>Loss of epithelial Gq and G11 signaling inhibits TGF? production but promotes IL-33-mediated macrophage polarization and emphysema.</gtr:title><gtr:parentPublicationTitle>Science signaling</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/2cc10d22d69f590782e2539a923e5cc7"><gtr:id>2cc10d22d69f590782e2539a923e5cc7</gtr:id><gtr:otherNames>John AE</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1945-0877</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/B7B401B6-095F-47D1-96C0-1561215535C0"><gtr:id>B7B401B6-095F-47D1-96C0-1561215535C0</gtr:id><gtr:title>An Epithelial Integrin Regulates the Amplitude of Protective Lung Interferon Responses against Multiple Respiratory Pathogens.</gtr:title><gtr:parentPublicationTitle>PLoS pathogens</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/cc5bef4b062f2cdb9692530a4cf168d5"><gtr:id>cc5bef4b062f2cdb9692530a4cf168d5</gtr:id><gtr:otherNames>Meliopoulos VA</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2016-01-01</gtr:date><gtr:issn>1553-7366</gtr:issn></gtr:publication><gtr:publication url="http://gtr.rcuk.ac.uk:80/publication/905DCDB9-E248-4D2F-9D1D-9682C2C5A04A"><gtr:id>905DCDB9-E248-4D2F-9D1D-9682C2C5A04A</gtr:id><gtr:title>Assessment of the effect of potential antifibrotic compounds on total and aV?6 integrin-mediated TGF-? activation.</gtr:title><gtr:parentPublicationTitle>Pharmacology research &amp; perspectives</gtr:parentPublicationTitle><gtr:authors><gtr:author url="http://gtr.rcuk.ac.uk:80/person/64d9176f6c0de92ec73bcd9db91881ac"><gtr:id>64d9176f6c0de92ec73bcd9db91881ac</gtr:id><gtr:otherNames>Porte J</gtr:otherNames></gtr:author></gtr:authors><gtr:date>2014-01-01</gtr:date><gtr:issn>2052-1707</gtr:issn></gtr:publication></gtr:publications><gtr:identifiers><gtr:identifier type="RCUK">G0901226</gtr:identifier></gtr:identifiers><gtr:healthCategories><gtr:healthCategory><gtr:id>E3CED108-9B11-45C4-A81B-3730D641CA68</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>Respiratory</gtr:text></gtr:healthCategory></gtr:healthCategories><gtr:researchActivities><gtr:researchActivity><gtr:id>3BEA012A-C817-4067-8BE1-05331EBB5152</gtr:id><gtr:percentage>100</gtr:percentage><gtr:text>4.2  Evaluation of markers and technologies</gtr:text></gtr:researchActivity></gtr:researchActivities><gtr:researchSubjects/><gtr:researchTopics/><gtr:rcukProgrammes/></gtr:project></gtr:projectComposition></gtr:projectOverview>